YOKNEAM, Israel--(BUSINESS WIRE)--EndoCross, Ltd. ( www.endocross.com ), which has developed a simple and cost-effective method for crossing the most challenging lesions in the percutaneous treatment of blocked coronary arteries, announced today that it has already enrolled one-third of the patients planned for the first-in-human study of its ENABLER-C Catheter System for Crossing Coronary Chronic Total Occlusions (“ENABLER 3C” study). The ENABLER 3C clinical study is taking place at the Institut Cardiovasculaire Paris-Sud under principal investigator Dr. Yves Louvard.
Help employers find you! Check out all the jobs and post your resume.
